MMTX — MindMaze Therapeutics Holding SA Share Price
0.000.00%
Last trade - 00:00- CH₣421.94m
- CH₣411.34m
- CH₣8.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.93 | ||
| Price to Tang. Book | 205.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 104.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.39% | ||
| Return on Equity | -41.61% | ||
| Operating Margin | -484.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | n/a | 3.32 | 6.08 | 6.03 | 8.42 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MindMaze Therapeutics Holding SA, formerly known as RELIEF THERAPEUTICS Holding SA, is a Switzerland-based company that engages in research, development, production, and sale of biotechnology, pharmaceutical, diagnostic, therapeutic, chemical, and cosmetic products. The Company acquires and manages patents, licenses, and intellectual property, provides preclinical, clinical, and regulatory services, and may establish subsidiaries worldwide. The Company also participates in the acquisition, holding, and financing of interests in companies, offers management services to affiliates, and develops scientific and economic solutions for disease treatment and therapeutic approaches. Additionally, the Company may acquire, hold, and sell trademarks and other IP rights globally, and provide or obtain financing through loans or guarantees to support its corporate purpose.
Directors
- Raghuram Selvaraju CHM (40)
- Jack Weinstein CFO (65)
- Taneli Jouhikainen COO (54)
- Gilles Della Corte OTH
- Christiaan Stijnen OTH (58)
- Paolo Galfetti DRC
- Patrice Jean DRC
- Thomas Plitz DRC (53)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- June 13th, 2017
- Public Since
- September 19th, 2011
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 152,602,044
- Address
- Avenue de Secheron 15, GENEVE, 1202
- Web
- https://relieftherapeutics.com/
- Phone
- +41 447235959
- Contact
- Jeremy Meinen
- Auditors
- Forvis Mazars
Upcoming Events for MMTX
Relief Therapeutics Holding SA Annual Shareholders Meeting
Similar to MMTX
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
What is the MindMaze Therapeutics Holding SA share price?
As of Today at 21:04 UTC, shares in MindMaze Therapeutics Holding SA are trading at CH₣2.77. This share price information is delayed by 15 minutes.
How has the MindMaze Therapeutics Holding SA share price performed this year?
Shares in MindMaze Therapeutics Holding SA last closed at CH₣2.77 and the price had moved by -47.39% over the past 365 days. In terms of relative price strength the MindMaze Therapeutics Holding SA share price has underperformed the FTSE Global All Cap Index by -55.2% over the past year.
What are the analyst and broker recommendations for MindMaze Therapeutics Holding SA?
There is no consensus recommendation for this security.
Find out moreWhat is the MindMaze Therapeutics Holding SA dividend yield?
MindMaze Therapeutics Holding SA does not currently pay a dividend.
Does MindMaze Therapeutics Holding SA pay a dividend?
MindMaze Therapeutics Holding SA does not currently pay a dividend.
When does MindMaze Therapeutics Holding SA next pay dividends?
MindMaze Therapeutics Holding SA does not currently pay a dividend.
How do I buy MindMaze Therapeutics Holding SA shares?
To buy shares in MindMaze Therapeutics Holding SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MindMaze Therapeutics Holding SA?
As of the previous close price of CH₣2.77, shares in MindMaze Therapeutics Holding SA had a market capitalisation of CH₣421.94m.
Where are MindMaze Therapeutics Holding SA shares listed?
Here are the trading details for MindMaze Therapeutics Holding SA:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: MMTX
What kind of share is MindMaze Therapeutics Holding SA?
Based on an overall assessment of its quality, value and momentum MindMaze Therapeutics Holding SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MindMaze Therapeutics Holding SA share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the MindMaze Therapeutics Holding SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MindMaze Therapeutics Holding SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -13.76%.
As of the last closing price of CH₣2.77, shares in MindMaze Therapeutics Holding SA were trading +6.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MindMaze Therapeutics Holding SA PE Ratio?
The MindMaze Therapeutics Holding SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣2.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MindMaze Therapeutics Holding SA?
MindMaze Therapeutics Holding SA's management team is headed by:
- Raghuram Selvaraju - CHM
- Jack Weinstein - CFO
- Taneli Jouhikainen - COO
- Gilles Della Corte - OTH
- Christiaan Stijnen - OTH
- Paolo Galfetti - DRC
- Patrice Jean - DRC
- Thomas Plitz - DRC